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Evidence for Spread of a Clonal Strain of Pseudomonas aeruginosa
among Cystic Fibrosis Clinics
Recent advances in molecular typing techniques have led to
the identification of a dominant clonal strain of Pseudomonas
aeruginosa within several cystic fibrosis (CF) clinics (2–6, 8, 9).
These strains have been described as “hypertransmissible,” and
“patient-to-patient” spread has been implied. We report the
first isolation of a genetically identical clone of P. aeruginosa
from five CF clinics along the Eastern Seaboard of Australia
separated by a total distance of 1,800 km. In three of these
clinics, the strain has been identified as the dominant strain.
Using a combination of pulsed-field gel electrophoresis
(PFGE) and random amplified polymorphic DNA assays, we
previously identified a dominant clone (pulsotype I) of P.
aeruginosa affecting 55% of patients capable of expectorating a
sputum sample in a large pediatric/adolescent CF clinic in
Melbourne (2). This strain has been shown to be genetically
distinct from the epidemic strains found in the United King-
dom in Liverpool (8) and Manchester (6).
Subsequent screening using only PFGE (1) has identified
pulsotype I as being the dominant strain in a large adult CF
clinic 800 km away in Sydney. Thus far, 107 P. aeruginosa
isolates from 32 patients have been tested. Sixteen (50%) of
these patients have been identified as carrying pulsotype I. In
addition, three of eight (38%) patients thus far tested at a
Sydney pediatric CF center have also been shown to carry
pulsotype I.
Eight (five adults, three pediatric patients) of 100 patients
tested a further 1,000 km away in Brisbane (i.e., 1,800 km north
of the original site) have also been shown to carry pulsotype I,
although this was not the dominant strain at these centers.
Four of these patients are known to have relocated from Syd-
ney. No association with patients from either Sydney or Mel-
bourne could be identified for the remaining patients.
Exchange of representative samples between the laborato-
ries at the three clinics has confirmed the presence of pulso-
type I in each of the centers. In general, pulsotype I exhibits
multiple antibiotic resistance and frequently has a mucoid phe-
notype. No definite association with increased virulence has
been established.
Previously it had been thought that patients with CF were
generally infected for prolonged periods by unique lineages of
environmentally acquired P. aeruginosa (7). More recent stud-
ies have identified dominant or hypertransmissible strains
within a single clinic setting (2–6, 8, 9).
This is the first report of the same strain of P. aeruginosa
being identified in patients from five CF clinics in three geo-
graphically dispersed regions separated by large distances. In
three of these clinics, pulsotype I has been found to be the
dominant strain, while preliminary data from a fourth pediatric
center suggest that it may also be the dominant strain at that
site.
Despite extensive environmental testing both within and
outside of the hospital environments, we have been unable to
identify any environmental or nosocomial source of pulsotype
I.
The isolation of the same pulsotype from several CF clinics
separated by large distances, its dominance (approximately
50% of patients) in a number of these clinics, and the failure to
isolate this pulsotype from either the hospital or external en-
vironment are strongly indicative of P. aeruginosa being trans-
missible from patient to patient.
This suggests that P. aeruginosa cross-infection may be more
common than previously believed. We recommend more wide-
spread use of molecular surveillance for P. aeruginosa in large
CF clinics. If cross-infection is shown to be present, then co-
hort segregation of patients harboring P. aeruginosa and those
that are not, as well as patients with different strains of P.
aeruginosa, may be advisable.
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